









Opioid Conversion in Adults with Cancer MASCC-ASCO-AAHPM-HPNA-NICSO Guideline

Davis MP, et al.

Overview

- 1. Background & Methodology
 - Introduction
 - ASCO Guideline Development Methodology
 - Clinical Questions
 - Target Population and Audience
- 2. Summary of Recommendations
- 3. Discussion
 - Additional Resources
 - Expert Panel Members











1

Background & Methodology

Introduction

- Cancer pain and other serious illnesses often require opioid therapy.
- Most patients respond to the first opioid, although a significant number develop dose-limiting side effects or experience suboptimal pain control despite appropriate opioid titration.^{1,2}
- Opioid rotation or switching is often done to reduce side effects and/or improve pain control.²⁻¹³
- Opioid switches or rotations are successful due to inter-individual differences in opioid pharmacodynamics between individuals based on their opioid receptor genetics. 14-17
- Opioid conversion ratios provide the safe dose between withdrawal and toxicity for a population but should not be referred to as the "equianalgesic" dose.
- Further dose adjustments are likely to be needed in order for patients to experience optimal analgesia and/or reduced side effects.^{4,18,19}

Supportive Care in Cancer (MASCC).











Introduction

- A survey of 370 palliative care professionals from 53 countries collected opioid doses and routes used in practice.
- A significant difference in conversion ratios was observed across different clinician groups and geographical regions.¹⁰
- The present guideline seeks to reduce this variability by providing recommendations regarding opioid conversion in adults with cancer.
- It builds upon a recent ASCO guideline that addressed use of opioids for pain from cancer or cancer treatment.²⁰

Supportive Care in Cancer (MASCC).












ASCO Guideline Development Methodology

- The ASCO Evidence Based Medicine Committee (EBMC) guideline process includes:
 - a systematic literature review by ASCO guidelines staff
 - an expert panel provides critical review and evidence interpretation to inform guideline recommendations
 - final guideline approval by ASCO EBMC
- Due to limitations of the available evidence, recommendations were developed using the ASCO-modified Delphi formal consensus methodology.²¹ The 14 members of the Expert Panel were supplemented by 27 additional experts, who were recruited to rate their agreement with the recommendations.
- The full ASCO Guideline methodology manual can be found at: www.asco.org/guideline- methodology













Clinical Questions

This clinical practice guideline addresses three clinical questions:

- What assessments are important before opioid conversion?
- How should opioid conversions be conducted?
- What assessments are important after opioid conversion?











Target Population and Audience

Target Population

Adults with cancer who are receiving opioids for pain

Target Audience

 Oncologists, palliative care specialists, oncology nurses, oncology pharmacists, hospitalists, primary care clinicians, adults with cancer, and caregivers of adults with cancer

Supportive Care in Cancer (MASCC).











2

Summary of Recommendations

Clinical Question 1

What assessments are important before opioid conversion?

Recommendation 1.1

Recommended pre-conversion assessments include the following:

a. A multidimensional pain assessment, completed at the initial evaluation and periodically based on clinical circumstances, worsening pain severity or distress, or changes in pain characteristics (location, quality, etc.).

b. A thorough review of the pain pathology and other management options (e.g., disease modification, non-opioid analgesics, interventional techniques, and non-pharmacological interventions).

c. A review of comorbidities, drug-to-drug interactions, and cumulative adverse effects to identify factors that may indicate or contraindicate specific opioid analgesics or routes of administration.

n agreed/n voted	
------------------	--

% agreement

38/39

97.4%


39/39

100%

39/39

100%















Recommendation 1.1 (cont.)

			:	11 f _	11
Recommended	pre-conversion	assessments	include:	tne to	IIOWINA:
1 1000111111011404		accountionito	IIIOIAAO	$\mathbf{u} \cdot \mathbf{v} \cdot \mathbf{v}$	nownig.
	•				

d. A history of opioid analgesic usage, i.e., adherence, dosage, efficacy, route of administration, and tolerability.

e. Any history of drug misuse, abuse, addiction, and/or diversion in patients and family members (i.e., alcohol, opioids, and other drugs), or history of adverse childhood events.

f. An evaluation for organ dysfunction (e.g., hepatic or renal).

g. The availability of family members or friends to monitor the patient closely during the first few days after the opioid conversion.

h. A discussion with the patient and their family caregivers about the acceptability of different treatments (i.e., drug, route of administration).

n agreed/n voted	% agreement
39/39	100%

38/39 97.4%

38/39 97.4%

37/39 94.8%

33/39 84.6%











Recommendation 1.2

- Situations in which opioid conversion may be offered include the following:
 - a. If pain is uncontrolled despite upward titration of the current opioid analgesic or if the patient cannot tolerate the dose increase of the current opioid.
 - b. If intolerable adverse effects, such as itching, nausea, etc., persist despite tapering the opioid analgesic, and/or if symptomatic management of adverse effects is ineffective or poorly tolerated and pain is poorly controlled.
 - c. If signs of opioid-induced neurotoxicity, like allodynia, confusion, excessive drowsiness, hallucination, hyperalgesia, or myoclonus, occur or persist even after the tapering of the current opioid analgesic.
 - d. If pharmacokinetic factors affect the absorption, metabolism, or excretion of the current opioid analgesic.
 - e. If there are availability issues or health economic constraints (drug costs).

n agreed/n voted	% agreement
37/39	94.8%

38/39 97.4%

35/39	89.7%

39/39	100%
39/39	100%

37/39	94.8%
-------	-------











Recommendation 1.3

• If pain is uncontrolled, a change in the opioid route of administration from oral to intravenous or subcutaneous administration (to enable rapid titration) may be appropriate before changing opioids.

n agreed	/n voted	t

% agreement

37/39 | 94.8%

Note 1.

 The panel recommends that the assessment of "total pain," defined as emotional, social, and spiritual suffering, isolation, and distress due to financial problems, should be completed because it may influence the patient's perception of pain or self-report and, consequently, the choice of analgesic treatment. 37/39

94.8%



Supportive Care in Cancer (MASCC).

All rights reserved worldwide.
For licensing opportunities, contact licensing@asco.org.
Created with permission from the Multinational Association of











Note 2.

 The panel defines opioid conversion (also referred to as opioid rotation and/or switching) as either a change of the drug (opioid) or a change of the route of administration or formulation.

n agreed/n voted
35/39

% agreement 89.7%











Clinical Question 2

How should opioid conversions be conducted?

Recommendation 2.1

 Opioid doses should be individually adjusted based on patient characteristics, polypharmacy, organ function, and patient-clinician mutually agreed-upon targets for pain intensity and physical function. n agreed/n voted

37/39

% agreement

94.8%



Supportive Care in Cancer (MASCC).

©American Society of Clinical Oncology (ASCO) 2025.
All rights reserved worldwide.
For licensing opportunities, contact licensing@asco.org.
Created with permission from the Multinational Association of











Recommendation 2.2

 An option for converting from one opioid to another is to use a twostep process. The first step is to calculate the so-called "morphine equivalent daily dose" (MEDD) of the first opioid. The second step uses the calculated morphine equivalent daily dose of the second opioid in conversion. n agreed/n voted

35/39

% agreement

89.7%

Recommendation 2.3

Conversion ratios should not be confused with equianalgesia.
 Conversion ratios are the doses of an opioid anticipated to prevent withdrawal or overdose when changing opioids or routes of administration. Doses will need to be adjusted to achieve analgesia for the individual patient.

33/39

84.6%













Recommendation 2.4

Opioid choices in conversion should consider safety and utility. If
patients are at risk for addiction or have a history of addiction or
substance use disorder, one should consider buprenorphine or
methadone. If the patient has significant renal dysfunction,
buprenorphine, fentanyl, or methadone should be considered. If the
patient has significant liver disease, hydromorphone, or morphine
should be considered.

n agreed/n voted

30/38

% agreement

78.9%













Recommendation 2.5

 Clinicians should know drug interactions when using tramadol and codeine and be aware of medications that block CYP2D6, with tramadol in particular.

n agreed/n voted
37/38

% agreement 97.3%

Note for Recommendation 2.5

The analgesia of codeine and tramadol is influenced by CYP2D6 metabolizer status, and drug
interactions at CYP2D6 will alter conversion ratios. Ultra-rapid metabolizers with multiple
CYP2D6 alleles may have a greater conversion of codeine to morphine, resulting in opioid
toxicity if standard conversion ratios are used. Poor metabolizers do not convert tramadol to
desmethyl-tramadol and are likely to have a poor analgesic response to tramadol using
standard conversion ratios. Medications that block CYP2D6 may do the same.











Recommendation 2.6

 If converting from another opioid to methadone, a clinician experienced in prescribing methadone as an analgesic, aware of methadone's unique drug interactions, cardiac toxicity, and vast interindividual differences in pharmacokinetics and pharmacodynamics should be the clinician who manages the conversion to methadone. n agreed/n voted

38/38

% agreement

100%

Recommendation 2.7

 Multiple strategies can convert a potent opioid to methadone. These strategies include A. "stop-start," B. an "overlap," and C. an "as needed" strategy. Clinicians who prescribe methadone should be comfortable with at least one dosing strategy, preferably more than one strategy.

38/38

100%



©American Society of Clinical Oncology (ASCO) 2025. All rights reserved worldwide.

For licensing opportunities, contact licensing@asco.org. Created with permission from the Multinational Association of Supportive Care in Cancer (MASCC).











Recommendation 2.8

 Though methadone has a long half-life as an analgesic, the daily doses should be divided and given twice or thrice daily if used as an analgesic.

n agreed/n voted
32/35

% agreement 91.4%

Recommendation 2.9

 For breakthrough pain, 10-15% of the MEDD should be used initially to manage breakthrough pain using an immediate-release opioid, preferably the same one used to treat chronic pain. Rapid-acting fentanyl preparations are an alternative. Doses should be adjusted based on the response defined as a 30-50% reduction in pain severity.

30/38

78.9%



©American Society of Clinical Oncology (ASCO) 2025. All rights reserved worldwide.

For licensing opportunities, contact licensing@asco.org. Created with permission from the Multinational Association of Supportive Care in Cancer (MASCC).











Recommendation 2.10

 For breakthrough pain, the rescue dose of either immediate-release opioid or rapid-onset fentanyl needs to be individually titrated, given the poor correlation between the around-the-clock effective dose required to control the background pain and the dose needed to control the breakthrough pain.

n agreed/n voted

30/38

% agreement

78.9%

Note.


 If converting from a full opioid agonist to buprenorphine, patients may experience opioid withdrawal depending on the dose of the potent opioid and the initial buprenorphine dose in a "stop-start" conversion strategy.

27/34

79.4%



©American Society of Clinical Oncology (ASCO) 2025. All rights reserved worldwide.













Opioid Conversion Ratios that Reached Consensus

Converting from	Converting to	Recommended conversion ratios*	n agreed/n voted, % agreement
Oral morphine	Oral oxycodone	1.5:1	34/38, 89.4%
Oral morphine	Oral hydromorphone	5:1	33/37, 89.1%
Oral morphine	Oral oxymorphone	3:1	16/20, 80%
Parenteral morphine	Parenteral alfentanil	10:1	15/18, 83.3%
Oral oxycodone	Oral morphine	Between 1:1 and 1:2*	32/38, 84.2%
Oral oxycodone	Oral oxymorphone	2:1	17/19, 89.4%
Oral oxycodone	Oral tapentadol	1:5	20/24, 83.3%
Oral oxycodone	Intravenous oxycodone	2:1	22/25, 88%
Oral hydrocodone	Oral morphine	1:1	23/26, 88.4%
Oral hydrocodone	Oral oxycodone	1.5:1	21/26, 80.7%
Oral tramadol	Oral morphine	10:1	29/36, 80.5%
Oral codeine	Oral hydrocodone	8:1	18/22, 81.8%
Oral tapentadol	Oral morphine	3:1	21/25, 84%
Subcutaneous administration (any opioid)	Intravenous administration (any opioid)	1:1	33/36, 91.6%

^{*}A range was provided because of variability between the study conversion ratios

www.asco.org/supportive-care-guidelines

©American Society of Clinical Oncology (ASCO) 2025. All rights reserved worldwide.

For licensing opportunities, contact licensing@asco.org. Created with permission from the Multinational Association of Supportive Care in Cancer (MASCC).











Clinical Question 3

What assessments are important after opioid conversion?

Recommendation 4.1

Recommended post-conversion assessments include the following:

Pain severity rating using a validated scale. This should include the least and worst pain intensity.

Pain severity at rest and with movement using a validated scale.

Pain severity rating compared to the patient's personal pain severity goal.

Pain-related functional impacts on daily living activities.

n agreed/n voted		%
	i	

agreement 86.8%

36/38

33/38

94.7%


35/38

92.1%

37/38

97.3%















Recommendation 4.1 (cont.)

- Recommended post-conversion assessments include the following:
 - The average number of daily doses of short-acting opioids used for breakthrough pain.
 - f. The adverse effects of pain on mood (anxiety, depression) and sleep (e.g., sleep quality and quantity).

n	agreed/n	voted

% agreement

37/38

97.3%

38/38

100%

Recommendation 4.2

• Pain behaviors (such as agitation, facial expressions, etc.) should be evaluated regularly if patients cannot complete a pain intensity scale.

38/38

100%



©American Society of Clinical Oncology (ASCO) 2025. All rights reserved worldwide.

For licensing opportunities, contact <u>licensing@asco.org</u>.
Created with permission from the Multinational Association of Supportive Care in Cancer (MASCC).











Recommendation 4.3

Recommended adverse effect monitoring includes the following:

a.	New-onset drowsiness or sedation, the influence of the opioid conversion on the
	number of hours of sleep for 24 hours, and whether apnea or snoring develops
	or worsens at night.

 New-onset nausea or vomiting 	b.	New-onset	nausea	or	vomiting	٦.
--	----	-----------	--------	----	----------	----

- c. New onset confusion, delirium, and hallucinations.
- d. Abdominal discomfort, new-onset constipation, and/or stool frequency.
- e. New onset itching, scratching, pruritus, and/or rash.

n agreed/n voted		% agreement
36/38		94.7%

37/38 97.3%

38/38	100%
-------	------















Recommendation 4.4

 Dose adjustments should be made based on pain intensity, physical function, and side effects.

n agreed/n	voted

38/38

% agreement

100%


Recommendation 4.5

 After opioid conversion, ask patients and/or caregivers about missing opioid medications or doses when asked to fill the opioid prescription early or if a pill count demonstrates less medication than prescribed. 31/38

81.5%



©American Society of Clinical Oncology (ASCO) 2025.
All rights reserved worldwide.
For licensing opportunities, contact licensing@asco.org













Recommendation 4.6

Assess the affect (mood) of the patient, family, or formal caregivers.

n agreed/n voted

29/38

% agreement

76.3%

Recommendation 4.7


 A QTc interval should be monitored regularly on methadone, depending on the clinical circumstance. For example, a patient with cancer receiving curative treatment may require routine ECG (electrocardiogram) monitoring. In contrast, a patient with advanced cancer or those approaching the end of life will not require the same degree of monitoring.

31/37

83.7%



©American Society of Clinical Oncology (ASCO) 2025. All rights reserved worldwide.













Recommendation 4.8


 Reinforce the patient and caregivers' knowledge about pain assessment, the opioid administration schedule, and the need for ongoing monitoring for response and side effects with the new opioid.

n agreed/n voted	
------------------	--

38/38

% agreement

100%













3 Discussion

Additional Resources

 More information, including a supplement and clinical tools and resources, is available at <u>www.asco.org/supportive-care-guidelines</u>.

Patient information is available at <u>www.cancer.org</u>











Guideline Panel Members

Name	Affiliation/Institution
Mellar P. Davis, MD, co-chair	Geisinger Medical Center, Danville, PA
Carla Ripamonti, MD, co-chair	Network Italiano Cure di Supporto in Oncologia (NICSO), Universita' degli Studi di Brescia, Brescia, Italy
Robert M. Arnold, MD	Icahn School of Medicine at Mt Sinai, New York, NY
Eduardo Bruera, MD	University of Texas MD Anderson Cancer Center, Houston, Texas
Amy A. Case, MD	Roswell Park Comprehensive Cancer Center, Buffalo, NY
Gregory Crawford, MD	Northern Adelaide Local Health Network, Faculty of Health & Medical Sciences, University of Adelaide, South Australia, Australia
Andrew Davies, MBBS, MSc, MD	Trinity College Dublin, Dublin, Ireland
Mary Lynn McPherson, PharmD, PhD	University of Maryland, Baltimore, MD
Sebastiano Mercadante, MD	La Maddalena Cancer Center, Palermo, Italy
Judith A. Paice, PhD, RN	Northwestern University; Feinberg School of Medicine, Chicago, IL
Akhila S. Reddy, MD,	University of Texas MD Anderson Cancer Center, Houston, TX
Eric J. Roeland, MD	Oregon Health and Science University, Knight Cancer Institute, Portland, OR
Eriko Satomi, MD	Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan
Declan Walsh, MD	Atrium Health, Levine Cancer Center, Charlotte, NC
Kari Bohlke, ScD	American Society of Clinical Oncology (ASCO), Alexandria, VA

www.asco.org/supportive-care-guidelines

©American Society of Clinical Oncology (ASCO) 2025. All rights reserved worldwide.

For licensing opportunities, contact licensing@asco.org. Created with permission from the Multinational Association of Supportive Care in Cancer (MASCC).











Abbreviations

- AAHPM, American Academy of Hospice and Palliative Medicine
- ASCO, American Society of Clinical Oncology
- EBMC, Evidence Based Medicine Committee
- ECG, electrocardiogram
- HPNA, Hospice and Palliative Nurses Association
- MASCC, Multinational Association of Supportive Care in Cancer
- MEDD, morphine equivalent daily dose
- NICSO, Network Italiano Cure di Supporto in Oncologia











References

- Portenoy RK: Treatment of cancer pain. Lancet 377:2236-47, 2011
- 2. Mercadante S, Bruera E: Opioid switching in cancer pain: From the beginning to nowadays. Crit Rev Oncol Hematol 99:241-8, 2016
- 3. Treillet E, Laurent S, Hadjiat Y: Practical management of opioid rotation and equianalgesia. J Pain Res 11:2587-2601, 2018
- 4. Webster LR, Fine PG: Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med 13:562-70, 2012
- 5. Vissers KC, Besse K, Hans G, et al: Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 10:85-93, 2010
- 6. Vadalouca A, Moka E, Argyra E, et al: Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag 4:213-50, 2008
- 7. Twycross R: Opioid rotation: does it have a role? Palliat Med 12:60-3, 1998
- 8. Slatkin NE: Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 25:2133-50, 2009
- 9. Schuster M, Bayer O, Heid F, et al: Opioid Rotation in Cancer Pain Treatment. Dtsch Arztebl Int 115:135-142, 2018
- Reddy A, Sinclair C, Crawford GB, et al: Opioid Rotation and Conversion Ratios Used by Palliative Care Professionals: An International Survey. J Palliat Med 25:1557-1562, 2022
- 11. Nalamachu SR: Opioid rotation in clinical practice. Adv Ther 29:849-63, 2012
- 12. Mercadante S: Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856-66, 1999











References

- 13. Knotkova H, Fine PG, Portenoy RK: Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 38:426-39, 2009
- 14. Pasternak GW: Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 22:67-70, 2001
- 15. Pasternak GW, Childers SR, Pan YX: Emerging Insights into Mu Opioid Pharmacology. Handb Exp Pharmacol 258:89-125, 2020
- 16. Pasternak GW: Mu Opioid Pharmacology: 40 Years to the Promised Land. Adv Pharmacol 82:261-291, 2018
- 17. Pasternak GW: Insights into mu opioid pharmacology the role of mu opioid receptor subtypes. Life Sci 68:2213-9, 2001
- 18. Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence R, et al: Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 38:418-25, 2009
- 19. Webster LR, Fine PG: Overdose deaths demand a new paradigm for opioid rotation. Pain Med 13:571-4, 2012
- 20. Paice JA, Bohlke K, Barton D, et al: Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol 41:914-930, 2023
- 21. Loblaw DA, Prestrud AA, Somerfield MR, et al: American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 30:3136-40, 2012











Disclaimer

The Clinical Practice Guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (ASCO) to assist clinicians in clinical decision making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating clinician, as the information does not account for individual variation among patients. Recommendations specify the level of confidence that the recommendation reflects the net effect of a given course of action. The use of words like "must," "must not," "should," and "should not" indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating clinician in the context of treating the individual patient. Use of the information is voluntary. ASCO does not endorse third party drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions. Any use of a brand or trade name is for identification purposes only. ASCO provides this information on an "as is" basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.

© 2025 American Society of Clinical Oncology, all rights reserved. For licensing opportunities, contact <u>licensing@asco.org</u>. Materials are the property of ASCO. Permission required for reuse; contact <u>permissions@asco.org</u>. Created with permission from the Multinational Association of Supportive Care in Cancer (MASCC).









